secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001437749-23-023158
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech Q2 2023 cash $32.2M; 33% CR/CRi in AML trial Phase 1B
-----------------------------------------------------------------------

- R&D expense $3.9M, G&A expense $2.5M; cash runway into Q3 2024.
- Phase 1B/2 Annamycin monotherapy for soft tissue sarcoma: 73% stable disease after 2 cycles.
- Phase 1B portion of Annamycin + Cytarabine for AML completed; 33% CR/CRi rate among 6 patients.
- European Phase 1 Annamycin AML results published in British Journal of Cancer Research.
- Retained Shareholder Intelligence Services to investigate potential naked short selling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923023158/0001437749-23-023158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923023158/mbrx20230808c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-023158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer